Dysregulation of fragile X mental retardation protein and metabotropic glutamate receptor 5 in superior frontal cortex of individuals with autism: a postmortem brain study

Table 2 Western blot analysis results for FMRP, mGluR5, GABRβ3 and NSE and their ratios in BA9^a

Children	Control	Autistic	Change	P value	Cohen's d
FMRP/NSE	0.08 ± 0.057	0.123 ± 0.069	↑53%	ns	0.66
mGluR5 dimer/NSE	0.158 ± 0.175	0.409 ± 0.101	↑159%	0.013^b	1.93^b
mGluR5 total/NSE	0.167 ± 0.182	0.443 ± 0.123	↑165%	0.014^b	1.90^b
mGluR5 dimer/mGluR5 total	0.867 ± 0.154	0.93 ± 0.042	↑7.2%	ns	0.66
GABRβ3/NSE	0.095 ± 0.052	0.161 ± 0.086	↑69%	ns	0.86^b
NSE	17.4 ± 0.642	19.20 ± 2.67	↑10.4%	ns	--
Adults	Control	Autistic	Change	P value	Cohen's d
FMRP/NSE	0.24 ± 0.094	0.107 ± 0.068	↓55%	0.017^b	1.74^b
mGluR5 dimer/NSE	0.186 ± 0.098	0.309 ± 0.188	↑66%	ns	0.74
mGluR5 total/NSE	0.191 ± 0.099	0.367 ± 0.187	↑92%	ns	1.05^b
mGluR5 dimer/mGluR5 total	0.974 ± 0.023	0.982 ± 0.011	↑0.8%	ns	0.50
GABRβ3/NSE	0.177 ± 0.082	0.186 ± 0.103	↑5.1%	ns	0.09
NSE	17.5 ± 3.17	18.8 ± 2.3	↑1.3%	ns	-

^aFMRP, fragile X mental retardation protein; mGluR5, metabotropic glutamate receptor 5; GABRβ3, γ-aminobutyric acid (GABA) A receptor β3; NSE, neuron-specific enolase; BA9, Brodmann's area 9; ns, not significant; ^bstatistically significant.

ISSN: 2040-2392